JP Morgan commented on Omnicare OCR in a report released today. In the report, JP Morgan was positive in its assessment of the company.
JP Morgan writes, "Omnicare views specialty as a core competency and a key growth driver
going forward. The company noted that it has a 360 degree view of the
industry, serving patients, providers, caregivers, nurses, physicians, and
manufacturers, and offers multiple growth platforms, including specialty
pharmacy, reimbursement support hub programs, patient assistance programs,
third-party logistics, and patient management programs for end of life care."
JP Morgan currently has an Overweight rating on JP Morgan and a price target of $34. Shares of OCR closed at $31.45 on Thursday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in